BIOENGINEER

Child recovers after probable blinatumomab lung injury and dose-escalation rechallenge

A case report describes a child with B-ALL who recovered from probable blinatumomab-associated lung injury and completed a ...

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated ...

IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial

Landmark results from the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab-dlle demonstrated a statistically significant and highly clinically meaningful improvement in ...